William Blair analyst Sami Corwin downgrades Akouos (NASDAQ:AKUS) from Outperform to Market Perform.
Biofrontera Inc. Announces Last Patient Enrolled In Phase 3 Clinical Study Evaluating Ameluz-PDT For The Treatment Of Basal Cell Carcinoma, Trial Results Expected In Mid-2024
Biofrontera Inc. (NASDAQ:BFRI) (the "Company"), a biopharmaceutical company specializing in the commercialization of dermatological products, announces that patient enrollment is now complete in the
